Nonalcoholic Fatty Liver Disease And Angiotensin-(1-7)

Nonalcoholic fatty liver disease (NAFLD), one of the fastest growing liver diseases in China, is considered to be the hepatic manifestation of metabolic syndrome (MS). Renin-angiotensin system (RAS) is considered to play an important role in the development of nonalcoholic fatty liver disease (NAFLD). The inhibition of RAS activation is an effective treatment of NAFLD. Angiotensin-(1-7)[Ang-(1-7)] is recognized as a bioactive peptidyl factor of RAS. Different from angiotensin II (Ang II), Ang-(1-7) is considered to ameliorate IR (insulin resistance), hepatic fibrosis, fat accumulation and portal hypertension, et al. Until now, there is no widely accepted, safely and efficient therapy for NAFLD. Ang-(1-7) may become a new treatment for NAFLD.